We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+31.44%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$719M
AUM Growth
-$27.1M
(-3.6%)
Cap. Flow
-$214M
Cap. Flow
% of AUM
-29.71%
Top 10 Holdings %
Top 10 Hldgs %
66.29%
Holding
201
New
72
Increased
18
Reduced
27
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travelers Companies
TRV
|
+$7.93M |
| 2 |
FNB Corp
FNB
|
+$7.61M |
| 3 |
Sherwin-Williams
SHW
|
+$7.06M |
| 4 |
Allstate
ALL
|
+$5.58M |
| 5 |
Willis Towers Watson
WTW
|
+$5.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$274M |
| 2 |
Celanese
CE
|
+$6.41M |
| 3 |
MON
Monsanto Co
MON
|
+$6.27M |
| 4 |
Bunge Global
BG
|
+$5.97M |
| 5 |
Air Products & Chemicals
APD
|
+$4.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.98% |
| 2 | Industrials | 5.93% |
| 3 | Healthcare | 5.67% |
| 4 | Technology | 4.78% |
| 5 | Communication Services | 1.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ameriprise Financial
AMP
$48.3B
| $1.77M | 0.25% |
11,896
-11,449
| -49% | -$1.6M |
|
|
BLUE
77
DELISTED
bluebird bio
BLUE
| $1.73M | 0.24% |
972
+211
| +28% | +$295K |
|
78
Federated Hermes
FHI
$4.55B
| $1.68M | 0.23% |
+56,439
| New | +$1.59M |
|
79
RingCentral
RNG
$4.66B
| $1.67M | 0.23% |
+40,037
| New | +$1.54M |
|
|
WP
80
DELISTED
Worldpay, Inc.
WP
| $1.66M | 0.23% |
+23,512
| New | +$1.6M |
|
|
RXDX
81
DELISTED
Ignyta, Inc.
RXDX
| $1.65M | 0.23% |
133,584
+41,023
| +44% | +$423K |
|
82
CSX Corp
CSX
$93.4B
| $1.63M | 0.23% |
+90,000
| New | +$1.54M |
|
83
US Bancorp
USB
$98.2B
| $1.61M | 0.22% |
30,000
-10,000
| -25% | -$523K |
|
|
CSOD
84
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $1.56M | 0.22% |
+38,546
| New | +$1.43M |
|
85
HealthEquity
HQY
$8.41B
| $1.54M | 0.21% |
+30,515
| New | +$1.42M |
|
|
AAMI
86
Acadian Asset Management
AAMI
$3.08B
| $1.48M | 0.21% |
99,216
+39,683
| +67% | +$566K |
|
87
Fidelity National Information Services
FIS
$23.1B
| $1.45M | 0.2% |
15,543
-23,187
| -60% | -$2.11M |
|
88
Western Alliance Bancorporation
WAL
$8.79B
| $1.38M | 0.19% |
26,000
-30,000
| -54% | -$1.47M |
|
|
ESPR
89
DELISTED
Esperion Therapeutics
ESPR
| $1.32M | 0.18% |
26,350
-14,616
| -36% | -$705K |
|
|
CLVS
90
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.32M | 0.18% |
+16,009
| New | +$1.27M |
|
91
Associated Banc-Corp
ASB
$5.83B
| $1.28M | 0.18% |
+53,000
| New | +$1.23M |
|
92
Radian Group
RDN
$5.18B
| $1.25M | 0.17% |
66,804
+24,388
| +57% | +$423K |
|
|
TSS
93
DELISTED
Total System Services, Inc.
TSS
| $1.21M | 0.17% |
18,506
-13,424
| -42% | -$868K |
|
94
Yelp
YELP
$1.45B
| $1.21M | 0.17% |
+27,929
| New | +$1.08M |
|
95
Cathay General Bancorp
CATY
$4.22B
| $1.17M | 0.16% |
29,000
-25,000
| -46% | -$923K |
|
|
FSTX
96
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $1.06M | 0.15% |
15,740
-8,905
| -36% | -$510K |
|
97
Wintrust Financial
WTFC
$10.8B
| $1.02M | 0.14% |
+13,000
| New | +$966K |
|
98
Green Dot
GDOT
$743M
| $1.01M | 0.14% |
+20,436
| New | +$906K |
|
99
Brighthouse Financial
BHF
$3.56B
| $974K | 0.14% |
+16,025
| New | +$914K |
|
|
FOMX
100
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $963K | 0.13% |
173,501
-3,987
| -2% | -$20.6K |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q3 2017 Portfolio in Review
As of Q3 2017, Crestline Management held 201 positions worth $719M, down 3.6% from $746M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Crestline Management withdrew a net $214M in Q3 2017, closing 81 positions and reducing 27 holdings. Its most notable exit was Celanese, an estimated $6.41M position sold in full.
By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 13% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Crestline Management opened a new position in Travelers Companies worth $7.78M.
- Crestline Management's largest Q3 2017 buy was Travelers Companies: 63,503 shares worth $7.78M.
- Crestline Management added most to FNB Corp in Q3 2017, an estimated $7.61M increase.
- Crestline Management's biggest Q3 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $274M.
- Crestline Management fully exited Celanese in Q3 2017, selling an estimated $6.41M.
- Crestline Management's ten largest holdings make up 66% of its $719M portfolio in Q3 2017.
- Crestline Management opened 72 new positions and closed 81 in Q3 2017.
- Crestline Management's portfolio value fell 3.6% quarter-over-quarter to $719M.
Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.